Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer

H. Choy, W. Akerley, H. Safran, S. Graziano, C. Chung

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Previously untreated patients with stages IlIa or IIIB non-small cell lung cancer entered this phase II study to evaluate the activity and toxicity of combined paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin and concurrent radiation. Patients received paclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration- time curve of 2/wk for 7 weeks with radiation to the primary tumor and regional lymph nodes (44 Gy) followed by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 1200 mg/m2 and carboplatin (area under the concentration-time curve of 6) 3 weeks apart. From March 1995 to February 1996, 23 patients entered the study and their overall response rate (complete plus partial responses) was 82%. The major toxicity was esophagitis. Nine patients (45%) had experienced grades 3 or 4 esophagitis by the end of the 7-week concurrent phase. Seven of the nine patients recovered from the esophagitis within 2 weeks and received the additional two cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve of 6). Only one patient (4%) had grade 4 pneumonitis; this patient also recovered within 2 weeks and received the final two doses of combined chemotherapy. Therapy with paclitaxel, carboplatin, and concurrent radiation is a promising treatment for patients with locally advanced non-small cell lung cancer; it has a high response rate and acceptable toxicity.

Original languageEnglish (US)
Pages (from-to)117-119
Number of pages3
JournalSeminars in Oncology
Volume23
Issue number6 SUPPL. 16
StatePublished - 1996

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Radiotherapy
Esophagitis
Radiation
Ilium
Neoplasms
Pneumonia
Lymph Nodes
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. / Choy, H.; Akerley, W.; Safran, H.; Graziano, S.; Chung, C.

In: Seminars in Oncology, Vol. 23, No. 6 SUPPL. 16, 1996, p. 117-119.

Research output: Contribution to journalArticle

Choy, H. ; Akerley, W. ; Safran, H. ; Graziano, S. ; Chung, C. / Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. In: Seminars in Oncology. 1996 ; Vol. 23, No. 6 SUPPL. 16. pp. 117-119.
@article{afc71afd85bd4e6988f67e58cea68c3e,
title = "Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer",
abstract = "Previously untreated patients with stages IlIa or IIIB non-small cell lung cancer entered this phase II study to evaluate the activity and toxicity of combined paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin and concurrent radiation. Patients received paclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration- time curve of 2/wk for 7 weeks with radiation to the primary tumor and regional lymph nodes (44 Gy) followed by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 1200 mg/m2 and carboplatin (area under the concentration-time curve of 6) 3 weeks apart. From March 1995 to February 1996, 23 patients entered the study and their overall response rate (complete plus partial responses) was 82{\%}. The major toxicity was esophagitis. Nine patients (45{\%}) had experienced grades 3 or 4 esophagitis by the end of the 7-week concurrent phase. Seven of the nine patients recovered from the esophagitis within 2 weeks and received the additional two cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve of 6). Only one patient (4{\%}) had grade 4 pneumonitis; this patient also recovered within 2 weeks and received the final two doses of combined chemotherapy. Therapy with paclitaxel, carboplatin, and concurrent radiation is a promising treatment for patients with locally advanced non-small cell lung cancer; it has a high response rate and acceptable toxicity.",
author = "H. Choy and W. Akerley and H. Safran and S. Graziano and C. Chung",
year = "1996",
language = "English (US)",
volume = "23",
pages = "117--119",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 16",

}

TY - JOUR

T1 - Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer

AU - Choy, H.

AU - Akerley, W.

AU - Safran, H.

AU - Graziano, S.

AU - Chung, C.

PY - 1996

Y1 - 1996

N2 - Previously untreated patients with stages IlIa or IIIB non-small cell lung cancer entered this phase II study to evaluate the activity and toxicity of combined paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin and concurrent radiation. Patients received paclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration- time curve of 2/wk for 7 weeks with radiation to the primary tumor and regional lymph nodes (44 Gy) followed by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 1200 mg/m2 and carboplatin (area under the concentration-time curve of 6) 3 weeks apart. From March 1995 to February 1996, 23 patients entered the study and their overall response rate (complete plus partial responses) was 82%. The major toxicity was esophagitis. Nine patients (45%) had experienced grades 3 or 4 esophagitis by the end of the 7-week concurrent phase. Seven of the nine patients recovered from the esophagitis within 2 weeks and received the additional two cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve of 6). Only one patient (4%) had grade 4 pneumonitis; this patient also recovered within 2 weeks and received the final two doses of combined chemotherapy. Therapy with paclitaxel, carboplatin, and concurrent radiation is a promising treatment for patients with locally advanced non-small cell lung cancer; it has a high response rate and acceptable toxicity.

AB - Previously untreated patients with stages IlIa or IIIB non-small cell lung cancer entered this phase II study to evaluate the activity and toxicity of combined paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin and concurrent radiation. Patients received paclitaxel 50 mg/m2/wk as a 1-hour infusion and carboplatin area under the concentration- time curve of 2/wk for 7 weeks with radiation to the primary tumor and regional lymph nodes (44 Gy) followed by a boost to the tumor (22 Gy). In addition, patients received two additional cycles of paclitaxel 1200 mg/m2 and carboplatin (area under the concentration-time curve of 6) 3 weeks apart. From March 1995 to February 1996, 23 patients entered the study and their overall response rate (complete plus partial responses) was 82%. The major toxicity was esophagitis. Nine patients (45%) had experienced grades 3 or 4 esophagitis by the end of the 7-week concurrent phase. Seven of the nine patients recovered from the esophagitis within 2 weeks and received the additional two cycles of paclitaxel 200 mg/m2 and carboplatin (area under the concentration-time curve of 6). Only one patient (4%) had grade 4 pneumonitis; this patient also recovered within 2 weeks and received the final two doses of combined chemotherapy. Therapy with paclitaxel, carboplatin, and concurrent radiation is a promising treatment for patients with locally advanced non-small cell lung cancer; it has a high response rate and acceptable toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0030463425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030463425&partnerID=8YFLogxK

M3 - Article

C2 - 9007137

AN - SCOPUS:0030463425

VL - 23

SP - 117

EP - 119

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 16

ER -